This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Silha, J. V. Articles by Murphy, L. J. Search for Related Content PubMed PubMed Citation Articles by Silha, J. V. Articles by Murphy, L. J.

Minireview: Insights from Insulin-Like Growth Factor Binding Protein Transgenic Mice

Departments of Physiology (J.V.S., L.J.M.) and Internal Medicine (L.J.M.), University of Manitoba, Winnipeg R3E 0W3, Canada

Address all correspondence and requests for reprints to: Liam J. Murphy, M.D., Ph.D., University of Manitoba, Department of Physiology, John Buhler Research Centre, 715 McDermot Avenue, Room 841A, Winnipeg MB R3E 3P4, Canada. E-mail: ljmurph{at}cc.umanitoba.ca.

The existence of abundant high affinity binding proteins for the IGFs, the IGF binding proteins (IGFBPs), was first demonstrated more than 40 yr ago in the very early days of somatomedin research. With the development of molecular techniques and transgenic and knockout mouse models, the nature, complexity, and redundancy of the IGFBPs have now started to be elucidated. Indeed the functional role of the circulating IGFs and the originally proposed endocrine somatomedin hypothesis have recently been questioned. The limited reports to date indicate that IGFBP knockout mice have few phenotypic manifestations. In contrast, overexpression of IGFBPs in transgenic mice is associated with manifestations that provide some insight into the physiological role of the binding proteins. The predominant effect of generalized or tissue-specific overexpression of the IGFBPs has been growth inhibition as would be anticipated from inhibition of the actions of IGF-I and -II. In addition, impaired glucose homeostasis and reduced fecundity have been observed in both IGFBP-1- and IGFBP-3-overexpressing transgenic mice. This review examines the data reported to date for transgenic mouse models that overexpress IGFBPs. In addition, data from transgenic mice that overexpress the acid-labile subunit, an important component of the ternary complex, have also been reviewed.

This article has been cited by other articles:

				A. Joseph D'Ercole and P. Ye Expanding the Mind: Insulin-Like Growth Factor I and Brain Development Endocrinology, December 1, 2008; 149(12): 5958 - 5962. [Abstract] [Full Text] [PDF]

				L. Liao, X. Chen, S. Wang, A. F. Parlow, and J. Xu Steroid Receptor Coactivator 3 Maintains Circulating Insulin-Like Growth Factor I (IGF-I) by Controlling IGF-Binding Protein 3 Expression Mol. Cell. Biol., April 1, 2008; 28(7): 2460 - 2469. [Abstract] [Full Text] [PDF]

				I. A. Murray and G. H. Perdew Omeprazole Stimulates the Induction of Human Insulin-Like Growth Factor Binding Protein-1 through Aryl Hydrocarbon Receptor Activation J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1102 - 1110. [Abstract] [Full Text] [PDF]

				M J E Walenkamp and J M Wit Genetic disorders in the GH IGF-I axis in mouse and man Eur. J. Endocrinol., August 1, 2007; 157(suppl_1): S15 - S26. [Abstract] [Full Text] [PDF]

				S. G. Murali, X. Liu, D. W. Nelson, A. K. Hull, M. Grahn, M. K. Clayton, J. E. Pintar, and D. M. Ney Intestinotrophic effects of exogenous IGF-I are not diminished in IGF binding protein-5 knockout mice Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2007; 292(6): R2144 - R2150. [Abstract] [Full Text] [PDF]

				P. Saenger, P. Czernichow, I. Hughes, and E. O. Reiter Small for Gestational Age: Short Stature and Beyond Endocr. Rev., April 1, 2007; 28(2): 219 - 251. [Abstract] [Full Text] [PDF]

				O. Shynlova, P. Tsui, A. Dorogin, B. L. Langille, and S. J. Lye Insulin-like Growth Factors and Their Binding Proteins Define Specific Phases of Myometrial Differentiation During Pregnancy in the Rat Biol Reprod, April 1, 2007; 76(4): 571 - 578. [Abstract] [Full Text] [PDF]

				Y. Ning, A. G. P. Schuller, S. Bradshaw, P. Rotwein, T. Ludwig, J. Frystyk, and J. E. Pintar Diminished Growth and Enhanced Glucose Metabolism in Triple Knockout Mice Containing Mutations of Insulin-Like Growth Factor Binding Protein-3, -4, and -5 Mol. Endocrinol., September 1, 2006; 20(9): 2173 - 2186. [Abstract] [Full Text] [PDF]

				L. Liao, R. K. Dearth, S. Zhou, O. L. Britton, A. V. Lee, and J. Xu Liver-Specific Overexpression of the Insulin-like Growth Factor-I Enhances Somatic Growth and Partially Prevents the Effects of Growth Hormone Deficiency Endocrinology, August 1, 2006; 147(8): 3877 - 3888. [Abstract] [Full Text] [PDF]

				J. R. A. Sherwin, T. C. Freeman, R. J. Stephens, S. Kimber, A. G. Smith, I. Chambers, S. K. Smith, and A. M. Sharkey Identification of Genes Regulated by Leukemia-Inhibitory Factor in the Mouse Uterus at the Time of Implantation Mol. Endocrinol., September 1, 2004; 18(9): 2185 - 2195. [Abstract] [Full Text] [PDF]

				W. Chen, K. V. Salojin, Q.-S. Mi, M. Grattan, T. C. Meagher, P. Zucker, and T. L. Delovitch Insulin-Like Growth Factor (IGF)-I/IGF-Binding Protein-3 Complex: Therapeutic Efficacy and Mechanism of Protection against Type 1 Diabetes Endocrinology, February 1, 2004; 145(2): 627 - 638. [Abstract] [Full Text] [PDF]

				J.-C. Goffard, L. Jin, H. Mircescu, P. Van Hummelen, C. Ledent, J.-E. Dumont, and B. Corvilain Gene Expression Profile in Thyroid of Transgenic Mice Overexpressing the Adenosine Receptor 2a Mol. Endocrinol., January 1, 2004; 18(1): 194 - 213. [Abstract] [Full Text] [PDF]

				M. Haluzik, S. Yakar, O. Gavrilova, J. Setser, Y. Boisclair, and D. LeRoith Insulin Resistance in the Liver-Specific IGF-1 Gene-Deleted Mouse Is Abrogated by Deletion of the Acid-Labile Subunit of the IGF-Binding Protein-3 Complex: Relative Roles of Growth Hormone and IGF-1 in Insulin Resistance Diabetes, October 1, 2003; 52(10): 2483 - 2489. [Abstract] [Full Text] [PDF]